Treatment of Hepatitis C Infection With Metalloporphyrins

• US 20100086519A1
• Filed: 10/02/2009
• Published: 04/08/2010
• Est. Priority Date: 10/03/2008
• Status: Abandoned Application

• Current Assignee: Charlotte Mecklenburg Hospital Authority
• Original Assignee: Charlotte Mecklenburg Hospital Authority
• Inventors: Bonkovsky, Herbert L., Hou, Weihong
• Application Number:
  US12/572,651
• Publication Number:
  US 20100086519A1
• Time in Patent Office: Days
• US Class Current: 424/85.400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/409 having four such rings, e.g. porphine derivatives, bilirubin, biliverdine hemin, hematin A61K31/555
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/14 for RNA viruses

Abstract

The present invention is directed to the treatment of hepatitis C infection with a metalloporphyrin. In particular, the present invention is based on the discovery that the NS5A protein plays a key role in HCV RNA replication by participating in polyprotein cleavage, interferon response and cellular signaling pathways. It has been found that metalloporphyrins, such as zinc porphyrins, induce post-translational down-regulation of HCV NS5A protein in an ubquitin-proteasome degradation pathway. That is, metalloporphyrins can be used to activate the ubiquitin-proteasomal pathway of NS5A protein catabolism. As a result, metalloporphyrins can be used to significantly suppress HCV viral replication in HCV infected cells.

Claims

1. A method of treating a mammal suffering from hepatitis C viral infection comprising reducing NS5A protein levels in cells infected with hepatitis C virus (HCV).

2. The method of claim 1, further comprising the step of enhancing polybubquitination of the NS5A protein.

3. The method of claim 1, further comprising the step of suppressing HCV by treating the infected cells with a metalloporphyrin.

4. The method of claim 3, wherein the metalloporphyrin is selected from the group consisting of zinc mesoporphyrin, zinc protoporphyrin cobalt mesoporphyrin, cobalt mesoporphyrin, and combinations thereof.

5. The method of claim 3, wherein the NS5A protein has a half-life that is reduced to between about 0.5 to 3 hours.

6. The method of claim 3, wherein the NS5A protein has a half-life that is reduced to about 1 to 1.2 hours.

7. A method for the treatment of hepatitis C viral infection in a host in need thereof comprising administration to said host a therapeutically effective amount of a metalloporphyrin.

8. The method of claim 7, wherein the metalloporhyrin is selected from the group consisting of zinc mesoporphyrins, zinc protoporphyrins, heme, zinc deuteroporphyrin, zinc deuteroporphyrin bisglycol, cobalt protoporphyrin, cobalt mesoporphyrin, cobalt deuteroporphyrin, cobalt deuteroporphyrin bisglycol, heme, iron mesoporphyrin, iron deuteroporphyrin, and iron deuteroporphyrin bisglycol.

9. The method of claim 7, wherein an amount of NS5A protein in HCV infected cells is reduced from about 60 to 95%.

10. The method of claim 7, wherein the metallophorpyrin comprises an albumin complex.

11. The method of claim 7, further comprising the step of administering an interferon.

12. The method of claim 7, further comprising the step of reducing a half life of NS5A protein in infected HCV cells to about 1 to 1.2 hours.

13. The method of claim 7, wherein the amount of metalloporphyrin administered is from about 0.1 to 20 milligrams per killogram of the host body weight.

14. The method of claim 7, further comprising the step of administering the metalloporphyrin orally.

16. A method for the treatment of HCV infection in a patient in need thereof comprising administration to said host a therapeutically effective amount of an active ingredient selected from the group consisting of zinc mesoporphyrins, zinc protoporphyrins, heme, zinc deuteroporphyrin, zinc deuteroporphyrin bisglycol, cobalt protoporphyrin, cobalt mesoporphyrin, cobalt deuteroporphyrin, cobalt deuteroporphyrin bisglycol, heme, iron mesoporphyrin, iron deuteroporphyrin, and iron deuteroporphyrin bisglycol.

17. The method of claim 16, further comprising the step of administering an interferon.

18. The method of claim 16, further comprising the step of reducing a half life of NS5A protein in infected HCV cells to about 1 to 1.2 hours.

19. The method of claim 16, wherein the amount of metalloporphyrin administered is from about 0.1 to 20 milligrams per killogram of the patient body weight.

20. A pharmaceutical formulation for the treatment of HCV infection comprising a about 10 to 80 milligrams of zinc protoporphyrin that is bound to human serum albumin in a molar ratio from about 10:

1 to 1;

1.